Trials / Sponsors / Ridgeback Biotherapeutics, LP
Ridgeback Biotherapeutics, LP
Industry · 4 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Perso SARS-CoV-2 Infection, COVID-19 | Phase 2 | 2020-06-19 |
| Completed | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) SARS-CoV 2 | Phase 2 | 2020-06-16 |
| Completed | COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy V Coronavirus | Phase 1 | 2020-04-10 |
| Available | Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR Ebola Virus Disease | — | — |